Form D · Biotechnology

Linnaeus Therapeutics, Inc.

Haddonfield, NJ · CIK 0001752026

Offering snapshot reported Apr 2, 2026 · SEC filing

Reported sold
$4.99M
Offering amount: $10M
Investors reported
26
Form D · investor count
Minimum accepted
$1
Reported outside-investor minimum
First sale
Feb 17, 2026
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$2.5M$4.99MFeb 27, 2026: $4,475,000.00Feb 27, 2026Mar 13, 2026: $4,792,000.00Mar 13, 2026Mar 31, 2026: $4,892,000.00Apr 2, 2026: $4,992,000.00Apr 2, 2026

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$4,475,000 → $4,992,000
  • Reported investors19 → 26

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 2, 2026Amendment$4,992,000$517,000vs Feb 27, 202626SEC filing
Mar 31, 2026Amendment$4,892,000$417,000vs Feb 27, 202626SEC filing
Mar 13, 2026Amendment$4,792,000$317,000vs Feb 27, 202625SEC filing
Feb 27, 2026Initial$4,475,000No comparison19SEC filing
Aug 22, 2025Initial$1,275,000No comparison3SEC filing
Dec 26, 2024Amendment$5,824,155$4,195,757vs Aug 12, 202412SEC filing
Aug 12, 2024Initial$1,628,398No comparison6SEC filing
Jan 26, 2023Initial$3,088,234No comparison8SEC filing
Aug 24, 2021Initial$4,344,675No comparison15SEC filing
Feb 8, 2019Initial$2,160,000No comparison3SEC filing
Sep 7, 2018Initial$2,160,000No comparison4SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-574940

Source: Form D, filed Apr 2, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Chris Arendt Director
James Demetriades Director
Nicholas T. Iatropoulos Director
John Lepping Director
Jack Lepping Director
Patrick Mooney Director, Executive
Christopher Natale Executive
Michael Poisel Director
Todd Thomson Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
30 Washington Avenue, Suite F
Haddonfield, NJ, 08033